ClinicalTrials.gg
RecruitingNCT05373771SCIENCEUpdated Aug 14, 2023

Sickle Cell Improvement: Enhancing Care in the Emergency Department

An interventional study of Care pathway in Sickle Cell Crisis, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Sep 2021, registered May 2022).
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5,328
Allocation
Randomized
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Vaso-Occlusive Crises with a site in United States — 13 open to participants now, 15 under way, 5 of them phase 3. Vaso-Occlusive Crises · United States.

Planned enrollment
Largest of 56
5,328 · median 63
Started
2021
with 5 others
No phase
9 of 60
4 open now
Primary completion
2026-08
later than 3 of 14 live
Registered
47th of 60
by date

Among the 60 studies in Vaso-Occlusive Crises with a site in United States, this one has the largest planned enrollment of the 56 interventional ones that give a count, is one of 6 that started in 2021, is one of 9 with no phase, reaches primary completion later than 3 of the 14 other live ones, and was the 47th registered.

Vaso-Occlusive Crises

104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.

Browse Vaso-Occlusive Crises studies →

Open to participants now

13 of the 60 studies in Vaso-Occlusive Crises with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Vaso-Occlusive Crises studies recruiting now, 7 (41%) set no upper age limit and 6 (35%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Vaso-Occlusive Crises with a site in United States, or all of them as a file.
02

Study summary

Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 36,000 children in the United States, approximately 90% of whom are Black. The disease is characterized by recurrent, severe pain crises which result in high rates of emergency department visits and hospitalizations, and decreased quality of life. The National Heart, Lung and Blood Institute, as well as the American Society of Hematology, have endorsed pain management guidelines regarding the timeliness of care for children presenting with these acute pain crises. These evidence-based guidelines are infrequently followed, resulting in increased pain and hospitalizations. In additional to other barriers to following the guideline, structural racism has been proposed as a significant contributor and the New England Journal of Medicine recently called for the institution of SCD-specific pain management protocols to combat structural racism and reduce time to opioid administration. The investigators' long-term goal is to improve the care and health outcomes of children with acute painful vaso-occlusive crisis treated in the emergency department. The overall aim of the investigators is to test a care pathway using multifaceted implementation strategies to increase guideline adherent care for children in the emergency department with acute painful vaso-occlusive crisis.

03

Conditions studied

  • Sickle Cell Crisis

Browse trials for

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ED visit for uncomplicated pain crisis
  • Sickle cell disease
  • Receipt of at least one opioid

Exclusion criteria

Exclusion Criteria:

  • Acute chest syndrome
  • Fever > 38.5 in the ED
  • priapism
  • sickle cell trait
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5,328 participants (estimated)

Study arms

  • Active comparator
    Post-intervention

    Other: Care pathway

  • No intervention
    Delayed intervention

Interventions

  • OtherCare pathway

    Implementation of care pathway as part of hybrid type 2 implementation effectiveness study

06

What researchers measure

Primary outcomes

  1. Timeliness of receipt of opioids

    The percent of patients who receive first dose of opioids within 60 minutes of arrival and subsequent doses within 30 minutes of previous dose

    Time frame: A maximum of about 6 hours as all opioids received during the ED stay will be captured

Secondary outcomes

  1. Median time to opioids

    Median time from arrival to first opioid and then subsequent opioids

    Time frame: A maximum of about 6 hours as all opioids received during the ED stay will be captured

  2. Percent of children hospitalized

    Disposition of hospitalization or discharge home

    Time frame: A maximum of about 6 hours as that is the typical maximum time to disposition for patients

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Outcome data gathered through central data Registry. It is a limited dataset. A public use dataset will be made available after the study consistent with NIH guidelines.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Aug 2026, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2022
First posted
May 13, 2022
StartActual
Sep 1, 2021
Primary completionEst.
Aug 31, 2026
CompletionEst.
Aug 31, 2027
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05373771
Collaborators
Pediatric Emergency Care Applied Research Network, Nemours Children's Health System
Responsible party
David Brousseau (Professor, Chair, Nemours Children's Health System) — Principal investigator
First posted
May 13, 2022
Start date
Sep 1, 2021
Primary completion
Aug 31, 2026 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Aug 14, 2023

Study contacts

David Brousseau, MD, MS
Contact
david.brousseau@nemours.org
(302) 651-4000
David Brousseau, MD, MS
principal investigator · Nemours Children's Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion